Acupuncture for Combat Post-traumatic Stress Disorder: Trial Development and Methodological Approach for a Randomized Controlled Clinical Trial

The requested reference [82d93970c79e4fcce78c938a49d6e19b32cc3cca] no longer exists in our database. It has been replaced by the current reference: [56d9ddcde95f8f3c6ab98f999aec162202111372]

Authors
Category Primary study
Pre-printResearchSquare
Year 2020
Background: Post-traumatic Stress Disorder (PTSD) is a significant public health problem, affecting approximately 7% of the general population and 13 – 18% of the combat Veteran population. The first study using acupuncture for PTSD in a civilian population showed large pre- to post-treatment effects for an empirically developed verum protocol, which was equivalent to group cognitive behavior therapy and superior to a wait-list control. The primary objective of this study is to determine both clinical and biological effects of verum acupuncture for combat-related PTSD in treatment-seeking U.S. Veterans. Methods: This is a two-arm, parallel-group, prospective randomized placebo-controlled clinical trial. The experimental condition is verum acupuncture and the placebo control is sham (minimal) acupuncture in 1-hour sessions, twice a week for 12 weeks. Ninety subjects will provide adequate power and will be allocated to group by an adaptive randomization procedure. The primary outcome is change in PTSD symptom severity from pre- to post-treatment. The secondary biological outcome is change from pre- to post-treatment in psychophysiological response, startle by electromyographic (EMG) eyeblink. Assessments will be conducted at pre-, mid-, post-, and 1-month post-treatment, blind to group allocation. Intent-to-treat analyses will be conducted. Discussion: The study results will be definitive because both clinical and biological outcomes will be assessed and correlated. Issues such as number needed for recruitment and improvement, use of sham acupuncture, choice of biological measure, and future research need will be discussed. Trial registration: ClinicalTrials.gov ID: NCT02869646
Epistemonikos ID: 77864a36634f0e3bda0e62bac90387806cb322ac
First added on: Nov 28, 2025